ArticleProbiotics and antimicrobial proteins2026
Antibacterial and Antibiofilm Efficacy of Endolysin LysEf-9 and Crude Bacteriocin Against Multidrug and Phage-Resistant Enterococci.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Experimental screening and structure-informed engineering of peptide-fused bacteriophage lysins with enhanced activity against Gram-negative bacteria.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A gene encoding endolysin LysEf-9 from the phage PEF9, a lytic enterococcal phage, was cloned and overexpressed in Escherichia coli. The expressed LysEf-9 protein with a concentration of 62.5 μg/mL reduced the turbidity and viability of E. faecalis JCM 7783 after 3 h of incubation. LysEf-9 showed stability at different pH (2-12) and withstood different temperature treatments up to 60 °C. In addition, it showed a wide spectrum against Enterococci. Phage vB_EfKS5 with antibacterial and antibiofilm properties against E. faecalis was isolated previously. The phage-resistant mutant was isolated and used as an indicator strain in the present study. A bacteriocin-producing E. faecalis strain was also isolated, and the cell-free supernatant (crude bacteriocin) was partially purified by ammonium sulfate precipitation. The crude bacteriocin showed a wide spectrum against Enterococcus spp. and lysed the phage-resistant mutant. Using LysEf-9 with the crude bacteriocin reduced the viable count of E. faecalis JCM 3378 by 2.45 log after 24 h. In addition, LysEf-9 with phage vB_EfKS5 retarded the growth of the phage-resistant mutant. The antibiofilm efficacy of LysEf-9 and crude bacteriocin was also determined. LysEf-9 lowered the viable count of E. faecalis JCM 7783, E. faecium No. 26, and the phage-resistant mutant in the 48-h biofilm by 3 log, 2 log, and 1.5 log, respectively. The combination of LysEf-9 with crude bacteriocin reduced the total viable count of the indicator strains by at least 3 logs. This study shows the strong antibacterial and antibiofilm activity of LysEf-9, and the activity was enhanced when used with crude bacteriocin or phage.
Indexed as
Identifiers
40482006What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.